Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population.

About this Publication
Title
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population.
Pubmed ID
25199624 (View this publication on the PubMed website)
Publication
Ann. Intern. Med. 2014 Nov; Volume 161 (Issue 9): Pages 627-633
Authors
Pinsky PF, Gierada DS, Hocking W, Patz EF, Kramer BS
Abstract

BACKGROUND: The NLST (National Lung Screening Trial) showed reduced lung cancer mortality in high-risk participants (smoking history of ≥30 pack-years) aged 55 to 74 years who were randomly assigned to screening with low-dose computed tomography (LDCT) versus those assigned to chest radiography. An advisory panel recently expressed reservations about Medicare coverage of LDCT screening because of concerns about performance in the Medicare-aged population, which accounted for only 25% of the NLST participants.

OBJECTIVE: To examine the results of the NLST LDCT group by age (Medicare-eligible vs. <65 years).

DESIGN: Secondary analysis of a group from a randomized trial (NCT00047385).

SETTING: 33 U.S. screening centers.

PATIENTS: 19 612 participants aged 55 to 64 years (under-65 cohort) and 7110 participants aged 65 to 74 years (65+ cohort) at randomization.

INTERVENTION: 3 annual rounds of LDCT screening.

MEASUREMENTS: Demographics, smoking and medical history, screening examination adherence and results, diagnostic follow-up procedures and complications, lung cancer diagnoses, treatment, survival, and mortality.

RESULTS: The aggregate false-positive rate was higher in the 65+ cohort than in the under-65 cohort (27.7% vs. 22.0%; P < 0.001). Invasive diagnostic procedures after false-positive screening results were modestly more frequent in the older cohort (3.3% vs. 2.7%; P = 0.039). Complications from invasive procedures were low in both groups (9.8% in the under-65 cohort vs. 8.5% in the 65+ cohort). Prevalence and positive predictive value (PPV) were higher in the 65+ cohort (PPV, 4.9% vs. 3.0%). Resection rates for screen-detected cancer were similar (75.6% in the under-65 cohort vs. 73.2% in the 65+ cohort). Five-year all-cause survival was lower in the 65+ cohort (55.1% vs. 64.1%; P = 0.018).

LIMITATION: The oldest screened patient was aged 76 years.

CONCLUSION: NLST participants aged 65 years or older had a higher rate of false-positive screening results than those younger than 65 years but a higher cancer prevalence and PPV. Screen-detected cancer was treated similarly in the groups.

PRIMARY FUNDING SOURCE: National Institutes of Health.

Related CDAS Studies
Related CDAS Projects